Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial

PURPOSE: Cetuximab in combination with chemotherapy is a standard-of-care first-line treatment regimen for patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC); however, the efficacy of cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX) has never before been proven in...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Shukui, Li, Jin, Wang, Liwei, Xu, Jianming, Cheng, Ying, Bai, Yuxian, Li, Wei, Xu, Nong, Lin, Li-zhu, Wu, Qiong, Li, Yunfeng, Yang, Jianwei, Pan, Hongming, Ouyang, Xuenong, Qiu, Wensheng, Wu, Kaichun, Xiong, Jianping, Dai, Guanghai, Liang, Houjie, Hu, Chunhong, Zhang, Jun, Tao, Min, Yao, Qiang, Wang, Junyuan, Chen, Jiongjie, Eggleton, S. Peter, Liu, Tianshu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2018
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324088/
https://www.ncbi.nlm.nih.gov/pubmed/30199311
http://dx.doi.org/10.1200/JCO.2018.78.3183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324088/
https://www.ncbi.nlm.nih.gov/pubmed/30199311
http://dx.doi.org/10.1200/JCO.2018.78.3183

Ejemplares similares